Last reviewed · How we verify
PIZV
At a glance
| Generic name | PIZV |
|---|---|
| Also known as | TAK-426 |
| Sponsor | Takeda |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of Purified Inactivated Zika Virus Vaccine (PIZV) in Healthy Adults (PHASE2)
- Safety, Immunogenicity, and Dose Ranging Study of Inactivated Zika Virus Vaccine in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PIZV CI brief — competitive landscape report
- PIZV updates RSS · CI watch RSS
- Takeda portfolio CI